Medeva may be the cure Fisons needs

AFTER MONTHS of bold restructuring that has changed the direction of the company, Fisons is taking its biggest gamble yet. Its plan to take over Medeva, a rival drugs company, is not only a clever strategic move - the entire future of Fisons may also hang on its success.

If it succeeds, the rapid conversion of Fisons from the sick man of the pharmaceuticals sector to a company with a bright future will be complete. If it fails, the restructuring will have left Fisons looking extremely exposed and possibly lacking the expertise to survive in its field.

That the company appears a credible predator for Medeva at all is a tribute to its resurrection. A year ago it was widely seen in the stock market as lacking direction or strategy. Sales were falling and it had few new products in development to make up the shortfall. Almost every large drug company in Europe and the United States had examined it as a takeover target and rejected it. It desperately needed strong medicine to survive.

This is what Stuart Wallis, the chief executive brought in late last year, has provided. In the space of a few weeks he dealt with the loss- making scientific instruments operation by selling it rather than shutting it down. Then, in an almost heretical move for a drugs company, he sold the research and development arm to Astra, the Swedish company, for £202m. The laboratory supplies arm is also expected to be sold.

All of this will raise in the region of £470m in cash for the company while saving it some £70m a year that used to go on research spending. These were the kind of bold decisions that many believe could only have been taken by an outsider to the industry. Mr Wallis was one of the directors involved in changing Bowater, the struggling paper company, into a successful packaging group. He has no background in pharmaceuticals.

What he has done, however, is to turn Fisons from a conventional drugs company researching its own products into one that buys in products and uses its substantial sales force to market them. This strips out the huge development costs of new drugs although it now means the company must find drugs in a late stage of development to "license in" from outside and then market.

But Mr Wallis's restructuring can be seen in another light, too. "It is classic conglomerate financing," says one analyst. "It's the kind of thing Bowater might have done. You write down the assets, sell off the loss-making bits, boost the share price, and then make an acquisition that will improve the earnings per share."

Either way, a link with Medeva makes perfect sense for Fisons. It would not only get its takeover, it would also be buying the company on which it is modelling itself. Medeva, under its chairman, Bernard Taylor, a former Glaxo executive, has grown rapidly as a drug marketing company. It has bought in several successful "late-stage development" drugs, including respiratory drugs and a promising hepatitis B vaccine that is to be marketed soon.

Medeva's sales last year were £239m compared with £450m at Fisons. But while Medeva's sales have soared sixfold in the last five years and growth could reach 20 per cent, Fisons's sales growth is steadily falling into single figures.

Until Fison's transformation, Medeva was virtually the only UK drugs company occupying this niche in the sector. To find, buy in and exploit successful drugs in an increasingly competitive market requires management with long experience of pharmaceuticals and wide contacts in the industry. Led by Mr Taylor, Medeva has this.

Fisons does not. All its experience is focused on research and development rather than buying new drugs on the open market. Capturing Medeva's expertise would solve that at a stroke.

"The easy bit for Fisons was changing the company," says Peter Laing, analyst at Salomon Brothers. "Now it has to survive in its new form. It will be left in an exposed position if it doesn't pull off the deal with Medeva. Companies would not rush to buy Fisons, even though it is more attractive now."

This is why Fisons may be willing to pay £3 a share or more for Medeva, valuing the company at £900m, compared with a current market price below 250p. It is also why the deal may in the end look more like a merger or a reverse takeover than an outright purchase by Fisons. The stock market would almost certainly take more comfort from a combined company run largely by Medeva executives than one controlled by the Fisons team. Indeed, the outcome of the deal talks will almost certainly hinge partly on how the jobs will be shared out.

But while Fisons has everything to gain, Medeva's motive for the deal is less clear. The fit between products, such as its respiratory products and Fisons' asthma drugs, makes sense. Moreover, Fisons brings a large European sales force, which Medeva lacks since most of its marketing effort is in the US.

Yet in the near term, its sales and earnings will almost certainly be impaired by linking up with Fisons. Pushing up the sales of the combined group will also become a mammoth task that will require the company to find some remarkable new drugs - not an easy job, even for Medeva's talented management.

For these reasons, Medeva will have to drive a hard bargain to justify the deal. It is said to have set a minimum of 280p in the negotiations so far, but its US shareholders - about half the investor base - may demand more. In the end Medeva may find it hard to accept anything less than £3 per share. Fisons may, ultimately, have to scrape together substantially more to clinch the deal.

Even then, the takeover is by no means in the bag. Most analysts give it a 50-50 chance. But if Mr Wallis does not pull it off and his company has to face the future on its own, things may start to look bleak for Fisons.

Start your day with The Independent, sign up for daily news emails
Life and Style
Arts and Entertainment
Rocky road: Dwayne Johnson and Carla Gugino play an estranged husband and wife in 'San Andreas'
filmReview: In the face of all-round devastation, even Dwayne 'The Rock' Johnson appears a little puny
Arts and Entertainment
Bright lights, big city: Melrose Avenue in Los Angeles by dusk
Harry Kane makes Paul Scholes' Premier League team of the season
footballPaul Scholes on the best players, managers and goals of the season - and the biggest disappointments
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Guru Careers: Pricing Analyst

£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...

Guru Careers: C# Project Team Lead

£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...

Day In a Page

Fifa corruption: The 161-page dossier that exposes the organisation's dark heart

The 161-page dossier that exposes Fifa's dark heart

How did a group of corrupt officials turn football’s governing body into what was, in essence, a criminal enterprise? Chris Green and David Connett reveal all
Mediterranean migrant crisis: 'If Europe thinks bombing boats will stop smuggling, it will not. We will defend ourselves,' says Tripoli PM

Exclusive interview with Tripoli PM Khalifa al-Ghweil

'If Europe thinks bombing boats will stop smuggling, it will not. We will defend ourselves'
Raymond Chandler's Los Angeles: How the author foretold the Californian water crisis

Raymond Chandler's Los Angeles

How the author foretold the Californian water crisis
Chinese artist who posted funny image of President Xi Jinping facing five years in prison as authorities crackdown on dissent in the arts

Art attack

Chinese artist who posted funny image of President Xi Jinping facing five years in prison
Marc Jacobs is putting Cher in the limelight as the face of his latest campaign

Cher is the new face of Marc Jacobs

Alexander Fury explains why designers are turning to august stars to front their lines
Parents of six-year-old who beat leukaemia plan to climb Ben Nevis for cancer charity

'I'm climbing Ben Nevis for my daughter'

Karen Attwood's young daughter Yasmin beat cancer. Now her family is about to take on a new challenge - scaling Ben Nevis to help other children
10 best wedding gift ideas

It's that time of year again... 10 best wedding gift ideas

Forget that fancy toaster, we've gone off-list to find memorable gifts that will last a lifetime
Paul Scholes column: With the Premier League over for another year, here are my end of season awards

Paul Scholes column

With the Premier League over for another year, here are my end of season awards
Heysel disaster 30th anniversary: Liverpool have seen too much tragedy to forget fateful day in Belgium

Liverpool have seen too much tragedy to forget Heysel

Thirty years ago, 39 fans waiting to watch a European Cup final died as a result of a fatal cocktail of circumstances. Ian Herbert looks at how a club dealt with this tragedy
Amir Khan vs Chris Algieri: Khan’s audition for Floyd Mayweather may turn into a no-win situation, says Frank Warren

Khan’s audition for Mayweather may turn into a no-win situation

The Bolton fighter could be damned if he dazzles and damned if he doesn’t against Algieri, the man last seen being decked six times by Pacquiao, says Frank Warren
Blundering Tony Blair quits as Middle East peace envoy – only Israel will miss him

Blundering Blair quits as Middle East peace envoy – only Israel will miss him

For Arabs – and for Britons who lost their loved ones in his shambolic war in Iraq – his appointment was an insult, says Robert Fisk
Fifa corruption arrests: All hail the Feds for riding to football's rescue

Fifa corruption arrests

All hail the Feds for riding to football's rescue, says Ian Herbert
Isis in Syria: The Kurdish enclave still resisting the tyranny of President Assad and militant fighters

The Kurdish enclave still resisting the tyranny of Assad and Isis

In Syrian Kurdish cantons along the Turkish border, the progressive aims of the 2011 uprising are being enacted despite the war. Patrick Cockburn returns to Amuda
How I survived Cambodia's Killing Fields: Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape the US

How I survived Cambodia's Killing Fields

Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape to the US
Stephen Mangan interview: From posh buffoon to pregnant dad, the actor has quite a range

How Stephen Mangan got his range

Posh buffoon, hapless writer, pregnant dad - Mangan is certainly a versatile actor